X 1. Cash Flow Positive Status - 5 years X 2. Purchase main building housing their cGMP registered facility for research, development, manufacturing and packaging of pharmaceutical products. X 3. Adderall IR $335 Million Approved and Launched X 4. Adderall XR $1.56 Billion Approved and Launched X 5. Double digit quarterly revenues in millions X 6. In house marketing and distribution: Kirko Kirkov, Doug Plassche and their teams X 7. Prasco/Burel Adderall agreement starting January 1st 2024 X 8. First shipment Adderall XR to PRASCO Dec 2023 X 9. DEA increases manufacturing quotas for Adderall & Vyvance X 10. Generic Vyvanse - $5.1 BILLION - FDA submission Dec 2023 X 11. FDA Acceptance of Generic OxyContin Sept 2023 __12. $50 million in yearly revenues __13. Generate revenues over $20 million/quarter __14. Generic OxyContin Approval -;FIRST TO FILE Aug 17, 2023 $720 Million __15. Prevail over Purdue in Generic OxyContin infringement suit - 6 month stay X 16. Lease additional manufacturing space and storage vault for new Needle Mover ANDAs Jan 2024 __17. European distribution - Dexcel partnership approval by Israeli Health __18. Full ownership of Adderall IR $ 335 Million __19. Full ownership of Adderall XR $ 1.56 Billion __20. Generic Concerta-$1.2 BILLION FDA submission __21. Vigabatrin - VigPoder approved Pyros $233 Million trade mark challenge __22. $100 million in yearly revenues __23. Dopamine Agonist (probably Requip XL or Mirapex ER). $12 Million __24. Patented Unique ADF (w/o naltrexone)-- NDA __25. Mikah ANDA (s) __26. Undisclosed ANDAs/NDAs __27. Antimetabolite ANDA- Methotrexate -$600 Million - unconfirmed __28. Undisclosed Antimetabolite ANDA- $42 Million __29. Generic Vyvanse Approval __30. DollarLand PPS __31. Uplist to the NASDAQ Exchange __32. ELTP Elite Pharmaceutical Buyout - approx 23 months __33. Vegas Baby !!!!!!!
Market Data 
Markets 
AI
